Review Article

Pancreatic Cancer: 80 Years of Surgery—Percentage and Repetitions

Birgir Gudjonsson

The Medical Clinic, Álfheimur 74, 104 Reykjavik, Iceland

Correspondence should be addressed to Birgir Gudjonsson; bgav@simnet.is

Received 5 April 2016; Accepted 1 June 2016

Academic Editor: Pablo Ramirez

Copyright © 2016 Birgir Gudjonsson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The incidence of pancreatic cancer is estimated to be 48,960 in 2015 in the US and projected to become the second and third leading causes of cancer-related deaths by 2030. The mean costs in 2015 may be assumed to be $79,800 per patient and for each resection $164,100. Attempt is made to evaluate the results over the last 80 years, the number of survivors, and the overall survival percentage.

Methods. Altogether 1230 papers have been found which deal with resections and reveal survival information. Only 621 of these report 5-year survivors. Reservation about surgery was first expressed in 1964 and five-year survival of nonresected survivors is well documented.

Results. The survival percentage depends not only on the number of survivors but also on the subset from which it is calculated. Since the 1980s the papers have mainly reported the number of resections and survival as actuarial percentages, with or without the actual number of survivors being reported. The actuarial percentage is on average 2.75 higher. Detailed information on the original group (TN), number of resections, and actual number of survivors is reported in only 10.6% of the papers. Repetition occurs when the patients from a certain year are reported several times from the same institution or include survivors from many institutions or countries. Each 5-year survivor may be reported several times. Conclusion. Assuming a 10% resection rate and correcting for repetitions and the life table percentage the overall actual survival rate is hardly more than 0.3%.

1. Introduction

Resections for pancreatic adenocarcinoma which Whipple et al. [1] initiated after earlier attempts by Codivilla [2] and Kausch [3] have now been carried out for 80 years. Opinions still differ as to the results. Some authors claim a survival percentage of up to 22% and are widely quoted and extol the benefits and success of resections [4] while others doubt that anyone survives pancreatic cancer [5].

2. Incidence, Economics

The incidence of pancreatic cancer has been estimated at 48,960 in 2015 in the US and is the fourth leading cause of death from cancer for both sexes [6]. It is projected to increase to 62,000 in the year 2020 and to 88,000 for both sexes in 2030 and to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related deaths by 2030 [7].

The cost of treatment of pancreatic cancer is of concern in many countries. O’Neill and colleagues studied the total direct medical cost of patients 66 years and older who were diagnosed from 2000 to 2007 in the US. The mean total direct cost was $65,500, for resectable locoregional disease cost was $134,700, and for unresectable locoregional or distant disease cost was $65,300 and $49,000, respectively [8]. Lea and Stahlgren had earlier pointed out the difference in the cost of resections versus bypass [9].

Assuming 2.5% inflation over 8 years, the mean cost in 2015 would be $79,800, for resections $164,100, for unresectable (or bypasses) disease $79,500, and for distant disease $59,700. With the estimated number of patients in 2015 the overall cost would be close to $4 billion.

3. Methods and Evaluation of Results

There is a growing concern that reports of success in medical research are inflated [10].

Here an attempt is made to evaluate the results over the last 80 years, the number of survivors, and the overall survival percentage.
4. Reservation, Nonresected Survivors

The first reservation about the effect of surgery on this disease was expressed by Glenn and Thorbjarnarson [11] in 1964, again by Gallitano et al. [12] in 1968 whose only 5-year survivor was “nonresected,” and then strongly by Crile Jr. in 1970 [13], whose only survivor was also nonresected. He challenged the value of resection for pancreatic cancer, followed by Shapiro in 1975 [14]. Crile Jr’s criticism was directed at the then high mortality rate and the survival calculations which were carried out and might count only those who survived the operation and in ignorance of the nonresected survivors.

The presence of nonresected survivors has been disputed [15], but it is a major issue in the debate on survival. It was first pointed out by Cattell and Young in 1957 [16] and, as above, later by Gallitano and Crile Jr. The data were summarized by the present author in a paper in 1995 [17] and a letter in 1996 [18]. In a review by the present author published in 1978 only 65 five-year survivors could be found in the literature, of whom 8 were nonresected [19]. In a review published in 1987, 165 survivors could be found, but 12 of these were nonresected [20]. In this review 41 reports have been found from 31 institutions in 12 countries, many from eminent institutions and renowned authors, thereof 17 from the US, two from Yale [19, 20], two from the University Texas MD Anderson [12, 21], and two from Harvard MGH [22, 23], as well as from the University of Chicago [24], the Dana Farber Cancer Clinic [25], and Thomas Jefferson [26], to mention a few.

Nonresected survival is a fact and should be kept in mind in assessing overall therapeutic results. Initially reports detailed the course of all patients diagnosed at a particular institution but in recent decades reports have concentrated only on resected patients, completely ignoring any nonresected survivors. Nonresected survivors would therefore not be found.

5. Survival Calculations

The survival percentage depends not only on the number of survivors but on the subset from which the number is calculated.

A few earlier studies started by examining the respective tumor registries and disclosed that only about 35–68% of patients in tumor registries had histologic confirmation. Survival calculations have been based on the original number of patients with histologic diagnoses at a particular institution, previously called the total number (TN), the approximately 80% of cases that were surgically explored, the cases that were resected, or location, size, or R status of the tumor, or even only those patients who survived the operation.

Overall survival success must be based on the original group diagnosed with pancreatic cancer (the TN or total number) and the number of survivors and not only on a small subgroup of the cases. Different methods of calculation have been used to enumerate the results, that is, actual versus the actuarial, projected, or estimated percentage.

Initially most papers revealed the TN, the number of resections, and simply the number of survivors, whereas later authors also presented actual percentage figures. In the late 1980s the papers started reporting only the number of resections and survival as actuarial percentages, usually calculated with the Kaplan–Meier method with or without the actual number of survivors being reported [27].

Sir Hill pointed out in his book in 1937 that when a “large number of patients is lost sight of” the outcome might be erroneously high. This warning is reemphasized in later editions [28]. In a frequently quoted paper 11 survivors out of 201 are claimed as proof of 22% survival [4].

As indicated in Table 1 the original number TN of patients studied in a report is only revealed in 90 or 14.5% of the papers and in these the actual number of survivors is stated in only 49. In the remaining 41 with a documented TN and actuarial calculation the actual number of survivors is stated in 17, in addition to life table curves. Detailed information on the original TN group studied, number of resections, and actual number of survivors is therefore reported in only 66 or 10.6% of all papers on pancreatic cancer. In the remaining 89.4% some form of estimate or calculation is required to assess survival percentage. In 531 papers there is no information on the original number of patients from which the number of resections was drawn, although in 102 of these the number of survivors is stated or confirmed by inquiry.

In 424 of these 531 reports with survival calculations by actuarial methods 378 are by the Kaplan–Meier method and 48 by other or unclear methods, though KM is also very likely. The number of survivors is stated in 147 of the reports or 34.6%, but not in the remaining 277 or 65.3%.
## Table 1: Survival information.

| Categories of reports                                      | Number of reports | Reports with/without survivors | Reports with/without stated TN | Reports with actuarial calculations and stated number of survivors | Reports with actuarial calculation and survivors confirmed by inquiry | Reports with actuarial calculations and estimated number of survivors |
|-------------------------------------------------------------|-------------------|--------------------------------|--------------------------------|------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| TN number of reports                                        | 1230              | 621                            | 90                            | 17                                                               | 7                                                                   | 17                                                                   |
| Reports with survivors                                      |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Reports with stated TN of patients                          |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Actual survival calculations                                |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Actuarial calculations with stated number of survivors      |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Actuarial calculation with survivors confirmed by inquiry   |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Reports with estimated number of survivors                  |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Reports with estimated TN of patients                       |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Actual survival calculations                                |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Reports with actuarial calculation and stated number of survivors |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Survivors confirmed by inquiry                              |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Estimated number of survivors                               |                   |                                |                               |                                                                  |                                                                     |                                                                      |
| Reports without survivors                                   |                   |                                |                               |                                                                  |                                                                     | 226                                                                  |


A total of 240 inquiries were sent to authors where the actual number of patients was not reported and only 58 replies were obtained. The actual number of survivors with actuarial calculation is therefore known in 205 of the 424 reports or 48.3%. The actuarial and actual percentage figures can therefore be compared, as demonstrated previously [29, 30], and reveal that the actuarial percentage is on average 2.75 higher than the actual percentage. This figure has therefore been used to estimate the number of survivors and the survival percentage in the relevant studies where only the actuarial percentage has been published.

The resection rate has been debatable and varies and can only be assessed accurately if the original group is large and well defined. Tertiary referral centers cannot know the size of the original group from which their resection group is drawn. Of the studies published in the last 5 years, 156 of 161 or 97% report only the number of resections and the percentages. In an earlier study by this author the resection rate was 10.8%. In earlier US studies [31, 32] the rate was, respectively, 8.4% and 12%. In 2 European nationals [33, 34] the rate was from 8% to 12% over the last 5 years. In a recent report from the surgical service at a European university hospital [35] the resection rate was 11.6%. It is therefore practical to assume that the resection rate is 10% in the studies where the original TN of the group is not reported in order to estimate the TN accordingly and divide the percentage by 2.5–3 where the actuarial KM only has been published.

After totaling the numbers in the 621 studies with survivors with the above correction, but without further adjustment, the TN comes to 1,731,834, the number of resected patients to 162,207, and the number of survivors to 11,300, for an apparent survival percentage of 0.77%.

After totaling the number of patients in all the 1230 reports, the original TN comes to 3,188,543, the number of resected patients to 284,298, and the number of survivors to 11,330. The overall survival percentage would then be only 0.45%.
6. Repetitions

Repetition of reporting the same survivors in different papers was first pointed out in 1978 [17]. It occurs in various ways, such as when papers include survivors from many different institutions or known databases in a specific country or even when a study includes patients from many countries. Thus 92 of the 620 studies with 5-year survivors are from many institutions in a specific country or 14.8% and 10 of these from many countries or 1.6%.

Repetition occurs, though mainly when the patient population and survivors from a certain year are reported several times from the same institution. As can be seen in Figures 1–5, repetition has occurred up to 6–8 times in Germany, Italy, and Japan and up to 20 times in the US.

Examination of reports from a single institution covering the entire study period and stating the number of survivors and then adding up the number of patients from all the studies, including those with an estimated number of survivors, reveals that the total number reported is over 10 times larger than the number reported in the studies with a documented number of survivors.

Each paper may at times reveal some new information but only infrequently is it disclosed that the patients have been reported before.

There is no scientific method to assess the number of repetitions accurately but each reported 5-year survivor and thereby respective resection and the TN seems to be reported 3–5 times. Dividing the number of reported survivors and respective resections and TN by 4, the overall number of 5-year survivors is hardly more than 2,800, the number of resections 40,500, and the original TN number of patients 433,000.

Repetitions occur also in the “no-survivor” group of reports, but not as frequently. It may be assumed that all published reports with or without survivors are drawn from a TN of approx. 1,000,000 patients and with fewer than 3,000 survivors, of whom a significant number were nonresected, meaning that the overall survival rate was no more than approximately 0.3%.

Figure 2: Repetitions Italy sample. See [66–91].
| Author                      | Years   | 95 | 90 | 90 | 00 | 10 | Srv |
|-----------------------------|---------|----|----|----|----|----|-----|
| Hiroshima U                 |         |    |    |    |    |    |     |
| Murakami Y [91]             | 1990–06 |    |    |    |    |    | 3 s |
| Murakami Y [92]             | 1992–08 |    |    |    |    |    | 3 s |
| Murakami Y [93]             | 1994–09 |    |    |    |    |    | 8 s |
| Murakami Y [94]             | 1996–10 |    |    |    |    |    | 6 s |
| Murakami Y [95]             | 2002–09 |    |    |    |    |    | 7 s |
| Kanazawa U                  |         |    |    |    |    |    |     |
| Kayahara M [96]             | 1970–95 |    |    |    |    |    | 2 s |
| Nagakawa T [97]             | 1973–90 |    |    |    |    |    | 7 s |
| Kayahara M [98]             | 1973–91 |    |    |    |    |    | 9 s |
| Nagakawa T [99]             | 1973–95 |    |    |    |    |    | 8 s |
| Nagakawa T [100]            | 1973–97 |    |    |    |    |    | 10 s|
| Nagakawa T [101]            | 1974–99 |    |    |    |    |    | 15 s|
| Nagakawa T [102]            | 1980–95 |    |    |    |    |    | 3 s |
| Kumamoto U                  |         |    |    |    |    |    |     |
| Hiraoka T [103]             | 1969–88 |    |    |    |    |    | 4 i |
| Hiraoka T [104]             | 1984–97 |    |    |    |    |    | 4 i |
| Takamori H [105]            | 1984–89 |    |    |    |    |    | 3 ? |
| Takamori H [106]            | 1984–89 |    |    |    |    |    | 6 s |
| Takamori H [107]            | 1984–89 |    |    |    |    |    | 3 ? |
| Kyoto U                     |         |    |    |    |    |    |     |
| Nakase A [108] 57 inst      | 1949–74 |    |    |    |    |    | 8 s |
| Manabe T [109]              | 1966–87 |    |    |    |    |    | 5 s |
| Manabe T [110]              | 1966–87 |    |    |    |    |    | 5 ? |
| Manabe T [111]              | 1969–87 |    |    |    |    |    | 5 ? |
| Kubo M [112]                | 1980–97 |    |    |    |    |    | 5 i |
| Imamura M [113]             | 1981–97 |    |    |    |    |    | 6 s |
| Hosotani R [114]            | 1982–95 |    |    |    |    |    | 5 s |
| Doi R [115]                 | 1980–99 |    |    |    |    |    | 2 s |
| Doi R [116] 19 inst         | 1977–02 |    |    |    |    |    | 1 s |
| Nagasaki U                  |         |    |    |    |    |    |     |
| Tsuji R [117] 19 inst       | 1977–79 |    |    |    |    |    | 4 s |
| Tsuji R [118] 441 inst      | 1966–80 |    |    |    |    |    | 35 s|
| Tsuji R [119] 444 inst      | 1966–83 |    |    |    |    |    | 9 i |
| Tsuji R [120] 441 inst      | 1975–84 |    |    |    |    |    | 11 i|
| Nanashima A [121]          | 1994–08 |    |    |    |    |    | 4 ? |
| Nagoya U                    |         |    |    |    |    |    |     |
| Nimura Y [122]              | 2000–03 |    |    |    |    |    | 9 s |
| Nakao A [123]               | 1981–00 |    |    |    |    |    | 17 ?|
| Nakao A [124]               | 1981–03 |    |    |    |    |    | 11 i|
| Nakao A [125]               | 1981–05 |    |    |    |    |    | 12 i|
| Yamada S [126]              | 2001–10 |    |    |    |    |    | 16 !!|
| Osaka Ctr Adult Dis, Med f Ca, CSM |   |    |    |    |    |    |     |
| Ishikawa O [127]            | 1960–94 |    |    |    |    |    | 14 s|
| Matsui Y [128]              | 1963–75 |    |    |    |    |    | 1 s |
| Miyata M [129]              | 1974–89 |    |    |    |    |    | 4 ? |
| Saka K [130] 59 inst        | 1980–90 |    |    |    |    |    | 23 ??|
| Ishikawa O [131]            | 1981–93 |    |    |    |    |    | 9 ? |
| Ishikawa O [132]            | 1981–95 |    |    |    |    |    | 20 ? |
| Ishikawa O [133]            | 1984–89 |    |    |    |    |    | 4 i |
| Ishikawa O [134]            | 1985–89 |    |    |    |    |    | 7 i |
| Ohigashi H [135]            | 1995–02 |    |    |    |    |    | 5 s |
| Ohigashi H [136]            | 2002–07 |    |    |    |    |    | 5 ??|
| Takahashi H [137]           | 2002–09 |    |    |    |    |    | 21 !!|
| Takahashi H [138]           | 2002–11 |    |    |    |    |    | 36 !!|
| Sendai U                    |         |    |    |    |    |    |     |
| Motoi F [139]               | 1989–08 |    |    |    |    |    | 13 ?|
| Sato T [140]                | 1960–76 |    |    |    |    |    | 1 s |
| Sato T [141]                | 1960–76 |    |    |    |    |    | 2 s |
| Matsuno S [142]             | 1960–85 |    |    |    |    |    | 2 s |
| Shibata C [143]             | 1983–98 |    |    |    |    |    | 5 i |

Figure 3: Continued.
7. Mortality, Positive Margins, and Nodes

Mortality during the first 20 years, 1945–1965, was on average 25.2% with a single report of 62.5%. During the next 20 years or up to 1984 mortality was on average 19.9% with the highest rate at 52%. In 1985–1994 it lowered to 9.8%. In subsequent 5-year periods mortality was reduced to 6.8% and then 4.6% and during the last 5 years 4% with a high of 33%. Aside from the 33%, the average is now 3.7%. The overall mortality rate has therefore greatly reduced.

The majority of surgeons in recent decades have reported the number of positive margins and nodes and numbers over
60–70% frequently quoted [36–38]. It is of great interest that even in the most experienced hands only 16% of cases were both margins and nodes negative [38].

Tumor cells can be found in the bone marrow in up to 50% of cases [39].

8. Discussion and Conclusion

Pancreatic cancer is thus both a costly and devastating disease and has usually spread beyond its boundaries at time of diagnosis and treatment and is thus a systemic disease. The literature on pancreatic surgery, while purporting to report the facts, is nevertheless inaccurate.

The use of actuarial calculation methods exaggerates the percentage and thereby the number of presumed survivors in a particular study.

Reporting the same patients repeatedly without any qualification gives a false impression of success.

Life table curves should be accompanied by the actual number of survivors. The course of nonresected patients should be studied.

Surgical skills are imperative for the care and palliation of pancreatic cancer patients including possible resections, but they have had only a minimal impact on the survival rate.

It is of importance for the medical profession that published results are indisputable.

Disclosure

The paper is based on 45 years of continuous study of the cancer of pancreas with previous communications and papers.

Competing Interests

The author declares that they have no competing interests.

Acknowledgments

The author thanks Terry G. Lacy Ph.D. for reviewing the manuscript.
References

[1] A. O. Whipple, W. B. Parsons, and C. R. Mullins, “Treatment of carcinoma of the ampulla of Vater,” *Annals of Surgery*, vol. 102, no. 4, pp. 763–776, 1935.

[2] J. M. Howard and W. Hess, *History of the Pancreas: Mysteries of a Hidden Organ*, Kluwer Academic/Plenum Publishers, New York, NY, USA, 2002.

[3] W. Kausch, “Das Carcinom der Papilla duodenii und seine radikale Entfernung,” *Beitrage zur Klinischen Chirurgie*, vol. 78, pp. 439–486, 1912.

[4] C. J. Yeo, J. L. Cameron, K. D. Lillemoe et al., “Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients,” *Annals of Surgery*, vol. 221, no. 6, pp. 721–733, 1995.

[5] M. Carpelan-Holmström, S. Nordling, E. Pukkala et al., “Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry,” *Gut*, vol. 54, no. 3, pp. 385–387, 2005.

[6] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” *CA Cancer Journal for Clinicians*, vol. 65, no. 1, pp. 5–29, 2015.

[7] L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman, and L. M. Matsri, “Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States,” *Cancer Research*, vol. 74, no. 11, pp. 2913–2921, 2014.

[8] C. B. O’Neill, C. L. Atoria, E. M. O'Reilly, J. Lafemina, M. C. Henman, and E. B. Elkin, “Costs and trends in pancreatic cancer treatment,” *Cancer*, vol. 118, no. 20, pp. 5132–5139, 2012.

[9] M. S. Lea and L. H. Stahlgren, “Is resection appropriate for adenocarcinoma of the pancreas? A cost-benefit analysis,” *The American Journal of Surgery*, vol. 154, no. 6, pp. 651–654, 1987.

[10] J. P. A. Ioannidis, “Why most published research findings are false,” *PLoS Medicine*, vol. 2, no. 8, article e124, 2005.

[11] F. Glenn and B. Thorbjarnarson, “Carcinoma of the pancreas,” *Annals of Surgery*, vol. 159, pp. 945–958, 1964.

[12] A. Gallitano, H. Fransen, and R. G. Martin, “Carcinoma of the results of treatment,” *Cancer*, vol. 22, no. 5, pp. 939–944, 1968.

[13] G. Crile Jr., “The advantages of bypass operations over radical pancreaticoduodenectomy in the treatment of pancreatic carcinoma,” *Surgery Gynecology and Obstetrics*, vol. 130, no. 6, pp. 1049–1053, 1970.

[14] T. M. Shapiro, “Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs whipple resection in good risk patients,” *Annals of Surgery*, vol. 182, no. 6, pp. 715–721, 1975.

[15] T. A. Gordon and J. L. Cameron, “Management of patients with carcinoma of the pancreas,” *Journal of the American College of Surgeons*, vol. 181, no. 6, pp. 558–560, 1995.

[16] R. B. Cattell and W. C. Young, “Long survival in a case of carcinoma of the pancreas,” *The Lahey Clinic Bulletin*, vol. 10, no. 5, pp. 131–134, 1957.

[17] B. Gudjonsson, “Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting,” *Journal of the American College of Surgeons*, vol. 181, no. 6, pp. 483–503, 1995.

[18] B. Gudjonsson, “Letter to the editor,” *Journal of the American College of Surgeons*, vol. 183, pp. 290–291, 1996.

[19] B. Gudjonsson, E. M. Livstone, and H. M. Spiro, “Cancer of the pancreas. Diagnostic accuracy and survival statistics,” *Cancer*, vol. 42, no. 5, pp. 2494–2506, 1978.

[20] B. Gudjonsson, “Cancer of the pancreas. 50 years of surgery,” *Cancer*, vol. 60, no. 9, pp. 2284–2303, 1987.

[21] M. H. G. Katz, P. W. T. Pisters, D. B. Evans et al., “Borderline resectable pancreatic cancer: the importance of this emerging stage of disease,” *Journal of the American College of Surgeons*, vol. 206, no. 5, pp. 833–846, 2008.

[22] J. Tepper, G. Nardi, and H. Suit, “Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy,” *Cancer*, vol. 37, no. 3, pp. 1519–1524, 1976.

[23] I. L. Konstantinidis, A. L. Warshaw, J. N. Allen et al., “Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection?,” *Annals of Surgery*, vol. 257, no. 4, pp. 731–736, 2013.

[24] F. Michelassi, F. Erroii, P. J. Dawson et al., “Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct,” *Annals of Surgery*, vol. 210, no. 4, pp. 544–556, 1989.

[25] M. K. Krzyzanowska, J. C. Weeks, and C. C. Earle, “Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness,” *Journal of Clinical Oncology*, vol. 21, no. 18, pp. 3409–3414, 2003.

[26] M. Mohiuddin, F. Rosato, D. Barbot, A. Schuricht, W. Biermann, and R. Cantor, “Long-term results of combined modality treatment with 1-125 implantation for carcinoma of the pancreas,” *International Journal of Radiation Oncology, Biology, Physics*, vol. 23, no. 2, pp. 305–311, 1992.

[27] E. L. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” *Journal of the American Statistical Association*, vol. 53, pp. 457–481, 1958.

[28] A. B. Hill, *Principles of Medical Statistics*, The Lancet Limited, London, UK, 1971.

[29] B. Gudjonsson, “Survival statistics gone awry: pancreatic cancer, a case in point,” *Journal of Clinical Gastroenterology*, vol. 35, no. 2, pp. 180–184, 2002.

[30] B. Gudjonsson, “Pancreatic cancer: survival, errors and evidence,” *European Journal of Gastroenterology and Hepatology*, vol. 21, no. 12, pp. 1379–1382, 2009.

[31] T. P. Wade, K. S. Virgo, and F. E. Johnson, “Distal pancreatectomy for cancer: results in U.S. Department of Veterans Affairs Hospitals, 1987–1991,” *Pancreas*, vol. 11, no. 4, pp. 341–344, 1995.

[32] S. B. Edge, R. E. Schmiegen Jr., L. K. Rosenlof, and M. C. Wilhelm, “Pancreas cancer resection outcome in American university centers in 1989–1990,” *Cancer*, vol. 71, no. 11, pp. 3502–3508, 1993.

[33] S. W. Nienhuij, S. A. van den Akker, E. de Vries, I. H. de Hing, O. Visser, and V. E. Lemmens, “Nationwide improvement of only short-term survival after resection for pancreatic cancer in the Netherlands,” *Pancreas*, vol. 41, no. 7, pp. 1063–1066, 2012.

[34] J. K. Bjerregaard, M. B. Mortensen, K. R. Schönhannem, and P. Pfeiffer, “Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients,” *European Journal of Cancer*, vol. 49, no. 1, pp. 98–105, 2013.

[35] J. K. ‘uchová, J. Bober, and J. Radoňan, “Postoperative complications and survival rates for pancreatic cancer patients,” *Wiener Klinische Wochenschrift*, vol. 123, no. 3–4, pp. 94–99, 2011.
[37] V. J. Picozzi, R. A. Kozarek, and L. W. Traverso, “Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma,” *American Journal of Surgery*, vol. 185, no. 5, pp. 476–480, 2003.

[38] J. Cameron, D. W. Crist, J. V. Sitzmann et al., “Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer,” *The American Journal of Surgery*, vol. 161, no. 1, pp. 120–125, 1991.

[39] K. Zgraggen, B. A. Centeno, C. Fernandez-Del Castillo, R. E. Jimenez, J. Werner, and A. L. Warshaw, “Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients,” *Surgery*, vol. 129, no. 5, pp. 537–546, 2001.

[40] D. Henne-Bruns, I. Vogel, J. Lütgges, G. Klöppel, and B. Kremer, “Ductal adenocarcinoma of the pancreatic head: survival after regional versus extended lymphadenectomy,” *Hepato-Gastroenterology*, vol. 45, no. 21, pp. 855–866, 1998.

[41] D. Henne-Bruns, I. Vogel, J. Lütgges, G. Klöppel, and B. Kremer, “Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy,” *World Journal of Surgery*, vol. 24, no. 5, pp. 595–602, 2000.

[42] J. Klempnauer, G. J. Ridder, H. Bektas, and R. Pichlmayr, “Surgery for exocrine pancreatic cancer. Who are the 5- and 10-year survivors?” *Oncology*, vol. 52, no. 5, pp. 353–359, 1995.

[43] J. Klempnauer, G. J. Ridder, and R. Pichlmayr, “Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head,” *British Journal of Surgery*, vol. 82, no. 12, pp. 1686–1691, 1995.

[44] J. Klempnauer, G. J. Ridder, H. Bektas, and R. Pichlmayr, “Extended resections of ductal pancreatic cancer—impact on operative risk and prognosis,” *Oncology*, vol. 53, no. 1, pp. 47–53, 1996.

[45] F. A. Wenger, F. Peter, J. Zieren, A. Steiert, C. A. Jacobi, and J. M. Müller, “Prognosis factors in carcinoma of the head of the pancreas,” *Digestive Surgery*, vol. 17, no. 1, pp. 29–35, 2000.

[46] H. Wolff and H. Lippert, “Das pankreaskarzinom aus der sicht des chirurgen,” *Zbl Chirurgie*, vol. 112, pp. 1–11, 1987.

[47] T. Bottger, J. Zech, W. Weber, K. Solger, and T. Junginger, “Relevant factors in the prognosis of ductal pancreatic carcinoma,” *Acta Chirurgica Scandinavica*, vol. 156, no. 11-12, pp. 781–788, 1990.

[48] T. C. Böttger, S. Stöckel, S. Wellek, M. Stöckle, and T. Junginger, “Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study,” *Cancer*, vol. 73, no. 1, pp. 63–73, 1994.

[49] M. Trede, G. G. Schwall, and H.-D. Saeger, “Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality,” *Annals of Surgery*, vol. 211, no. 4, pp. 447–458, 1990.

[50] A. Richter, M. Niedergethmann, D. Lorenz, J. W. Sturm, M. Trede, and S. Post, “Resection for cancers of the pancreatic head in patients aged 70 years or over,” *European Journal of Surgery*, vol. 168, no. 6, pp. 339–344, 2002.

[51] A. Richter, M. Niedergethmann, J. W. Sturm, D. Lorenz, S. Post, and M. Trede, “Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience,” *World Journal of Surgery*, vol. 27, no. 3, pp. 324–329, 2003.

[52] M. Hartel, M. Niedergethmann, M. Farag-Soliman et al., “Benefit of venous resection for ductal adenocarcinoma of the pancreatic head,” *European Journal of Surgery*, vol. 168, no. 12, pp. 707–712, 2002.
HPB Surgery

[71] P. Magistrelli, R. Masetti, R. Coppola et al., “Pancreatic resection for periampullary cancer in elderly patients,” *Hepato-Gastroenterology*, vol. 45, no. 19, pp. 242–247, 1998.

[72] A. G. Morganti, V. Valentini, G. Macchia et al., “Adjuvant radiotherapy in resectable pancreatic carcinoma,” *European Journal of Surgical Oncology*, vol. 28, no. 5, pp. 523–530, 2002.

[73] G. C. Mattiucci, E. Ippolito, G. R. D'Agostino et al., “Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma,” *Annals of Surgical Oncology*, vol. 20, no. 2, pp. 423–429, 2013.

[74] M. Reni, M. G. Panucci, A. J. M. Ferreri et al., “Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma,” *International Journal of Radiation Oncology Biology Physics*, vol. 50, no. 3, pp. 651–658, 2000.

[75] V. Dicarlo, G. Balzano, A. Zerbi, and E. Villa, “Pancreatic cancer resection in elderly patients,” *British Journal of Surgery*, vol. 85, no. 5, pp. 607–610, 1998.

[76] V. Di Carlo, A. Zerbi, G. Balzano, and V. Corso, “Pylorus-preserving pancreaticoduodenectomy versus conventional Whipple operation,” *World Journal of Surgery*, vol. 23, no. 9, pp. 920–925, 1999.

[77] A. M. Taschieri, M. Ellì, M. Cristaldi, G. Montecamozzo, T. Porretta, and P. G. Danelli, “Pancreatectomia totale vs pancreatectomia parziale nel trattamento chirurgico del carcinoma della testa del pancreas,” *Chirurgia Italiana*, vol. 46, pp. 44–50, 1994.

[78] A. M. Taschieri, M. Ellì, M. Rovati et al., “Surgical treatment of pancreatic tumors invading the spleno-mesenteric-portal vessels. An Italian multicenter survey,” *Hepato-Gastroenterology*, vol. 46, no. 25, pp. 492–497, 1999.

[79] G. Serio, C. Icono, G. Prati, E. Facci, G. Faleza, and A. Gorla, “La chirurgia resettiva per neoplasie pancreatiche negli ultimi venti anni,” *Chirurgia Italiana*, vol. 46, pp. 1–10, 1994.

[80] S. Crippa, S. Partelli, G. Zamboni et al., “Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?,” *Surgery*, vol. 152, no. 3, pp. S112–S119, 2012.

[81] G. Malleo, G. Marchegiani, R. Salvia, G. Butturini, P. Pederzoli, and C. Bassi, “Pancreatectoduodenectomy for pancreatic cancer: the verona experience,” *Surgery Today*, vol. 41, no. 4, pp. 463–470, 2011.

[82] C. Iacono, S. Accordini, L. Bortolasi et al., “Results of pancreatoduodenectomy for pancreatic cancer: extended versus standard procedure,” *World Journal of Surgery*, vol. 26, no. 11, pp. 1309–1314, 2002.

[83] G. Barugola, S. Partelli, S. Marcucci et al., “Resectable pancreatic cancer: who really benefits from resection?,” *Annals of Surgical Oncology*, vol. 16, no. 12, pp. 3316–3322, 2009.

[84] G. Barugola, S. Partelli, S. Crippa et al., “Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy,” *American Journal of Surgery*, vol. 203, no. 2, pp. 132–139, 2012.

[85] F. Mosca, P. C. Giulianotti, T. Balestracci et al., “La duodenocafalopancreatectomia con conservazione del piloro (PPPD) nel carcinoma pancreatico e periampolare,” *Chirurgia Italiana*, vol. 46, pp. 59–67, 1994.

[86] F. Mosca, P. C. Giulianotti, T. Balestracci et al., “Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreateo-duodenectomy,” *Surgery*, vol. 122, no. 3, pp. 553–566, 1997.

[87] S. Pedrazzoli, C. Sperti, and C. Pasquali, “Previsione della resecabilità e del rischio chirurgico del carcinoma pancreatico; fattori che condizionano la sopravvivenza dopo intervento reattivo,” *Chirurgia Italiana*, vol. 46, pp. 30–38, 1994.

[88] C. Sperti, B. Bonadimir, C. Pasquali et al., “Ductal adenocarcinoma of the pancreas. Clinicopathological features and survival,” *Tumori*, vol. 79, no. 5, pp. 325–330, 1993.

[89] C. Sperti, C. Pasquali, A. Piccoli, and S. Pedrazzoli, “Survival after resection for ductal adenocarcinoma of the pancreas,” *British Journal of Surgery*, vol. 83, no. 5, pp. 625–631, 1996.

[90] C. Sperti, C. Pasquali, A. Piccoli, and S. Pedrazzoli, “Recurrence after resection for ductal adenocarcinoma of the pancreas,” *World Journal of Surgery*, vol. 21, no. 2, pp. 195–200, 1997.

[91] C. Sperti, C. Pasquali, and S. Pedrazzoli, “Ductal adenocarcinoma of the body and tail of the pancreas,” *Journal of the American College of Surgeons*, vol. 185, no. 3, pp. 255–259, 1997.

[92] Y. Murakami, K. Uemura, T. Sudo et al., “Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma,” *Journal of Gastrointestinal Surgery*, vol. 12, no. 3, pp. 534–541, 2008.

[93] Y. Murakami, K. Uemura, T. Sudo et al., “Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma,” *Journal of the American College of Surgeons*, vol. 211, no. 2, pp. 196–204, 2010.

[94] Y. Murakami, K. Uemura, T. Sudo, Y. Hashimoto, Y. Yusa, and T. Suda, “Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma,” *World Journal of Surgery*, vol. 34, no. 8, pp. 1900–1907, 2010.

[95] Y. Murakami, K. Uemura, T. Sudo et al., “Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma,” *Journal of Surgical Oncology*, vol. 106, no. 2, pp. 174–180, 2012.

[96] Y. Murakami, K. Uemura, T. Sudo et al., “Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma,” *Journal of Surgical Oncology*, vol. 107, no. 4, pp. 414–421, 2013.

[97] M. Kayahara, T. Nagakawa, K. Ueno et al., “Distal pancreatectomy. Does it have a role for pancreatic body and tail cancer,” *Hepato-Gastroenterology*, vol. 45, no. 21, pp. 827–832, 1998.

[98] T. Nagakawa, I. Konishi, K. Ueno et al., “Surgical treatment of pancreatic cancer—the japanese experience,” *International Journal of Pancreatology*, vol. 9, no. 1, pp. 135–143, 1991.

[99] M. Kayahara, T. Nagakawa, K. Ueno, T. Ohta, Y. Tsukioka, and I. Miyazaki, "Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion," *Surgery*, vol. 117, no. 6, pp. 616–623, 1995.

[100] T. Nagakawa, M. Nagamori, F. Futakama et al., “Results of extensive surgery for pancreatic carcinoma,” *Cancer*, vol. 77, no. 4, pp. 640–645, 1996.

[101] T. Nagakawa, I. Konishi, K. Ueno, T. Ohta, M. Kayahara, and I. Miyazaki, "Extended radical pancreatectomy for carcinoma of the head of the pancreas; Hepato-Gastroenterology*, vol. 45, no. 21, pp. 849–854, 1998.

[102] T. Nagakawa, H. Sanada, M. Inagaki et al., "Long-term survivors after resection of carcinoma of the head of the pancreas: significance of histologically curative resection," *Journal of Hepato-Biliary-Pancreatic Surgery*, vol. 11, no. 6, pp. 402–408, 2004.

[103] T. Nagakawa, K. Ueno, T. Ohta et al., “Evaluation of long-term survivors after pancreateoduodenectomy for pancreaticduodenal...
carcinoma," Hepato-Gastroenterology, vol. 42, no. 2, pp. 117–122, 1995.

[104] T. Hiraoka, R. Uchino, K. Kanemitsu et al., "Combination of intraoperative radiation with resection of cancer of the pancreas," International Journal of Pancreatology, vol. 7, no. 1–3, pp. 201–207, 1990.

[105] T. Hiraoka and K. Kanemitsu, "Value of extended resection and intraoperative radiotherapy for resectable pancreatic cancer," World Journal of Surgery, vol. 23, no. 9, pp. 930–936, 1999.

[106] H. Takamori, T. Hiraoka, K. Kanemitsu, and T. Tsuji, "Pancreatic liver metastases after curative resection combined with intraoperative radiation for pancreatic cancer," Hepato-Gastroenterology, vol. 51, no. 59, pp. 1500–1503, 2004.

[107] H. Takamori, T. Hiraoka, K. Kanemitsu, T. Tsuji, C. Hamada, and H. Baba, "Identification of prognostic factors associated with early mortality after surgical resection for pancreatic cancer—under-analysis of cumulative survival curve," World Journal of Surgery, vol. 30, no. 2, pp. 213–218, 2006.

[108] H. Takamori, T. Hiraoka, K. Kanemitsu et al., "Long-term outcomes of extended radical resection combined with intraoperative radiation therapy for pancreatic cancer," Journal of Hepato-Biliary-Pancreatic Surgery, vol. 15, no. 6, pp. 603–607, 2008.

[109] A. Nakase, Y. Matsumoto, K. Uchida, and I. Honjo, "Surgical treatment of cancer of the pancreas and the peripancreatic region: cumulative results in 57 institutions in Japan," Annals of Surgery, vol. 185, no. 1, pp. 52–57, 1977.

[110] T. Manabe, G. Ohshio, N. Baba et al., "Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas," Cancer, vol. 64, no. 5, pp. 1132–1137, 1989.

[111] T. Manabe and T. Tobe, "Progress in the diagnosis and treatment of pancreatic cancer—The Kyoto University experience," Hepato-Gastroenterology, vol. 36, no. 6, pp. 431–436, 1989.

[112] T. Manabe, G. Ohshio, N. Baba, and T. Tobe, "Factors influencing prognosis and indications for curative pancreatectomy for ductal adenocarcinoma of the head of the pancreas," International Journal of Pancreatology, vol. 7, no. 1–3, pp. 187–193, 1990.

[113] M. Kokubo, Y. Nishimura, Y. Shibamoto et al., "Analysis of the clinical benefit of intraoperative radiotherapy in patients undergoing macroscopically curative resection for pancreatic cancer," International Journal of Radiation Oncology Biology Physics, vol. 48, no. 4, pp. 1081–1087, 2000.

[114] M. Imamura, R. Hosotani, and M. Kagire, "Rationale of the so-called extended resection for pancreatic invasive ductal carcinoma," Digestion, vol. 60, no. 1, pp. 126–129, 1999.

[115] R. Hosotani, M. Kagire, S. Ariti, Y. Nishimura, M. Hiraoka, and M. Imamura, "Results of pancreatectomy with radiation therapy for pancreatic cancer," Hepato-Gastroenterology, vol. 44, no. 18, pp. 1528–1535, 1997.

[116] R. Doi, H. Ikeda, H. Kobayashi, M. Kagire, and M. Imamura, "Carcinoma in the remnant pancreas after distal pancreatectomy for carcinoma," European Journal of Surgery, Supplement, vol. 168, no. 588, pp. 62–65, 2003.

[117] R. Doi, M. Imamura, R. Hosotani et al., "Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial," Surgery Today, vol. 38, no. 11, pp. 1021–1028, 2008.

[118] R. Tsuchiya, T. Oribe, and T. Noda, "Size of the tumor and other factors influencing prognosis of carcinoma of the head of the pancreas," American Journal of Gastroenterology, vol. 80, no. 6, pp. 459–462, 1985.

[119] R. Tsuchiya, T. Noda, N. Harada et al., "Collective review of small carcinomas of the pancreas," Annals of Surgery, vol. 203, no. 1, pp. 77–81, 1986.

[120] R. Tsuchiya, N. Harada, T. Tsunoda, T. Miyamoto, and K. Ura, "Long-term survivors after operation on carcinoma of the pancreas," International Journal of Pancreatology, vol. 3, no. 6, pp. 491–496, 1988.

[121] R. Tsuchiya, T. Tsunoda, and T. Yamaguchi, "Operation of choice for resectable carcinoma of the head of the pancreas," International Journal of Pancreatology, vol. 6, no. 4, pp. 295–306, 1990.

[122] A. Nanashima, S. Tobinaga, T. Abo et al., "Evaluation of surgical resection for pancreatic carcinoma at a Japanese single cancer institute," Hepato-Gastroenterology, vol. 59, no. 115, pp. 911–915, 2012.

[123] Y. Nimura, M. Nagino, S. Takao et al., "Standard versus extended lymphadenectomy in radical pancreateoduodenectomy for ductal adenocarcinoma of the head of the pancreas," Journal of Hepato-Biliary-Pancreatic Sciences, vol. 19, no. 3, pp. 230–241, 2012.

[124] A. Nakao, "Debate: extended resection for pancreatic cancer; the affirmative case," Journal of Hepato-Biliary-Pancreatic Surgery, vol. 10, no. 1, pp. 57–60, 2003.

[125] A. Nakao, S. Takeda, M. Sakai et al., "Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection," Pancreas, vol. 28, no. 3, pp. 289–292, 2004.

[126] A. Nakao, S. Takeda, S. Inoue et al., "Indications and techniques of extended resection for pancreatic cancer," World Journal of Surgery, vol. 30, no. 6, pp. 976–982, 2006.

[127] S. Yamada, T. Fujii, A. Nakao et al., "Aggressive surgery for borderline resectable pancreatic cancer: evaluation of national comprehensive cancer network guidelines," Pancreas, vol. 42, no. 6, pp. 1004–1010, 2013.

[128] O. Ishikawa, H. Ohigashi, S. Inaoka et al., "Minute carcinoma of the pancreas measuring 1 cm or less in diameter—collective review of Japanese case reports," Hepato-Gastroenterology, vol. 46, no. 25, pp. 8–15, 1999.

[129] Y. Matsui, Y. Aoki, O. Ishikawa et al., "Ductal carcinoma of the pancreas. Rationales for total pancreatectomy," Archives of Surgery, vol. 114, no. 6, pp. 722–726, 1979.

[130] M. Miyata, K. Nakao, T. Takao et al., "An appraisal of pancreatectomy for advanced cancer of the pancreas based on survival rate and postoperative physical performance," Journal of Surgical Oncology, vol. 45, no. 1, pp. 33–39, 1990.

[131] K. Satake, H. Nishiwaki, H. Yokomatsu et al., "Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas," Surgery Gynecology and Obstetrics, vol. 175, no. 3, pp. 239–265, 1992.

[132] O. Ishikawa, "Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas," Hepato-Gastroenterology, vol. 43, no. 8, pp. 320–325, 1996.

[133] O. Ishikawa, H. Ohigashi, Y. Sasaki et al., "Adjuvant therapies in extended pancreatectomy for ductal adenocarcinoma of the pancreas," Hepato-Gastroenterology, vol. 45, no. 21, pp. 644–650, 1998.

[134] O. Ishikawa, H. Ohigashi, S. Imaoka et al., "Preoperative indications for extended pancreatectomy for locally advanced pancreatic cancer involving the portal vein," Annals of Surgery, vol. 215, no. 3, pp. 231–236, 1992.
[164] R. R. Dalton, M. G. Sarr, J. A. Van Heerden, and T. V. Colby, "Carcinoma of the body and tail of the pancreas: is curative resection justified?" *Surgery*, vol. 111, no. 5, pp. 489–494, 1992.

[165] J. A. Van Heerden, "Pancreatic resection for carcinoma of the pancreas: whipple versus total pancreatectomy—an institutional perspective," *World Journal of Surgery*, vol. 8, no. 6, pp. 880–888, 1984.

[166] M. L. Foo, L. L. Gunderson, D. M. Nagorney et al., "Patterns of failure in grossly resected ductal adenocarcinoma treated with adjuvant irradiation ± 5 fluorouracil," *International Journal of Radiation Oncology, Biology, Physics*, vol. 26, no. 3, pp. 483–489, 1993.

[167] T. Schnelldorfer, A. L. Ware, M. G. Sarr et al., "Long-term survival after pancreateoduodenectomy for pancreatic adenocarcinoma: is cure possible?" *Annals of Surgery*, vol. 247, no. 3, pp. 456–462, 2008.

[168] J. Fatima, T. Schnelldorfer, J. Barton et al., "Pancreateoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival," *Archives of Surgery*, vol. 145, no. 2, pp. 167–172, 2010.

[169] S. Khan, G. Sclabas, K. Reid-Lombardo et al., "Does body mass index/morbid obesity influence outcome in patients who undergo pancreateoduodenectomy for pancreatic adenocarcinoma?" *Journal of Gastrointestinal Surgery*, vol. 14, no. 11, pp. 1820–1825, 2010.

[170] S. Khan, G. Sclabas, K. R. Lombardo et al., "Pancreateoduodenectomy for ductal adenocarcinoma in the very elderly: is it safe and justified?" *Journal of Gastrointestinal Surgery*, vol. 14, no. 11, pp. 1826–1831, 2010.

[171] S. S. Nitecki, M. G. Sarr, T. V. Colby, and J. A. Van Heerden, "Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving?" *Annals of Surgery*, vol. 221, no. 1, pp. 59–66, 1995.

[172] M. P. Spencer, M. G. Sarr, and D. M. Nagorney, "Radical pancreatectomy for pancreatic cancer in the elderly: is it safe and justified?" *Annals of Surgery*, vol. 212, no. 2, pp. 140–143, 1990.

[173] B. J. Billings, J. D. Christein, W. S. Harmsen et al., "Quality-of-life after total pancreatectomy: is it really bad on long-term follow-up?" *Journal of Gastrointestinal Surgery*, vol. 9, no. 8, pp. 1059–1067, 2005.

[174] C. C. Hsu, J. M. Herman, M. M. Corsini et al., "Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study," *Annals of Surgical Oncology*, vol. 17, no. 4, pp. 981–990, 2010.

[175] J. D. Christein, M. L. Kendrick, C. W. Iqbal, D. M. Nagorney, and M. B. Farnell, "Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas," *Journal of Gastrointestinal Surgery*, vol. 9, no. 7, pp. 922–927, 2005.

[176] M. B. Farnell, R. K. Pearson, M. G. Sarr et al., "A prospective randomized trial comparing standard pancreateoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma," *Surgery*, vol. 138, no. 4, pp. 618–630, 2005.

[177] M. Al-Haddad, J. K. Martin, J. Nguyen et al., "Vascular resection and reconstruction for pancreatic malignancy: a single center survival study," *Journal of Gastrointestinal Surgery*, vol. 11, no. 9, pp. 1168–1174, 2007.

[178] J. G. Barton, T. Schnelldorfer, C. M. Lohse et al., "Patterns of pancreatic resection differ between patients with familial and sporadic pancreatic cancer," *Journal of Gastrointestinal Surgery*, vol. 15, no. 5, pp. 836–842, 2011.

[179] K. P. Croome, M. B. Farnell, F. G. Que et al., "Total laparoscopic pancreateoduodenectomy for pancreatic ductal adenocarcinoma. Oncologic advances over open approaches," *Annals of Surgery*, vol. 260, no. 4, pp. 633–640, 2014.

[180] D. W. Crist, J. V. Sitzmann, and J. L. Cameron, "Improved hospital morbidity, mortality, and survival after the Whipple procedure," *Annals of Surgery*, vol. 206, no. 3, pp. 358–365, 1987.

[181] D. W. Crist and J. L. Cameron, "Current status of pancreateoduodenectomy for periampullary carcinoma," *Hepato-Gastroenterology*, vol. 36, no. 6, pp. 478–485, 1989.

[182] J. L. Cameron, T. S. Riall, J. Coleman, and K. A. Belcher, "One thousand consecutive pancreatectoduodenectomies," *Annals of Surgery*, vol. 244, no. 1, pp. 10–15, 2006.

[183] C. J. Yeo, T. A. Sohn, J. L. Cameron, R. H. Hruban, K. D. Lillemoe, and H. A. Pitt, "Periampullary adenocarcinoma: analysis of 5-year survivors," *Annals of Surgery*, vol. 227, no. 6, pp. 821–831, 1998.

[184] J. A. DiGiuseppe, C. J. Yeo, and R. H. Hruban, "Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas," *Advances in Anatomic Pathology*, vol. 3, no. 3, pp. 139–155, 1996.

[185] T. S. Riall, J. L. Cameron, K. D. Lillemoe et al., "Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up," *Surgery*, vol. 140, no. 5, pp. 764–772, 2006.

[186] M. A. Makary, J. M. Winter, J. L. Cameron et al., "Pancreatectoduodenectomy in the very elderly," *Journal of Gastrointestinal Surgery*, vol. 10, no. 3, pp. 347–356, 2006.

[187] J. M. Winter, J. L. Cameron, K. A. Campbell et al., "1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience," *Journal of Gastrointestinal Surgery*, vol. 10, no. 9, pp. 1199–1211, 2006.

[188] S. Reddy, C. L. Wolfgang, J. L. Cameron et al., "Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term Survival," *Annals of Surgery*, vol. 250, no. 2, pp. 282–287, 2009.

[189] I. H. Nordback, R. H. Hruban, J. K. Boitnott, H. A. Pitt, and J. L. Cameron, "Carcinoma of the body and tail of the pancreas," *The American Journal of Surgery*, vol. 164, no. 1, pp. 26–31, 1992.

[190] D. C. Allison, K. K. Bose, R. H. Hruban et al., "Pancreatic cancer cell DNA content correlates with long-term survival after pancreatectoduodenectomy," *Annals of Surgery*, vol. 214, no. 6, pp. 648–656, 1991.

[191] D. C. Allison, S. Piantadosi, R. H. Hruban et al., "DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma," *Journal of Surgical Oncology*, vol. 67, no. 3, pp. 151–159, 1998.

[192] J. He, B. H. Edil, J. L. Cameron et al., "Young patients undergoing resection of pancreatic cancer fare better than their older counterparts," *Journal of Gastrointestinal Surgery*, vol. 17, no. 2, pp. 339–344, 2013.

[193] G. E. McGuire, H. A. Pitt, K. D. Lillemoe, J. E. Niederhuber, C. J. Yeo, and J. L. Cameron, "Reoperative surgery for periampullary adenocarcinoma," *Archives of Surgery*, vol. 126, no. 10, pp. 1205–1212, 1991.

[194] J. W. Lin, J. L. Cameron, C. J. Yeo, T. S. Riall, and K. D. Lillemoe, "Risk factors and outcomes in postpancreatectoduodenectomy pancreaticocutaneous fistula," *Journal of Gastrointestinal Surgery*, vol. 8, no. 8, pp. 951–959, 2004.

[195] T. A. Sohn, C. J. Yeo, J. L. Cameron et al., "Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators," *Journal of Gastrointestinal Surgery*, vol. 4, no. 6, pp. 567–579, 2000.
[196] K. D. Lillemoe, J. L. Cameron, C. J. Yeo et al., "Pancreaticoduodenectomy: does it have a role in the palliation of pancreatic cancer?" *Annals of Surgery*, vol. 223, no. 6, pp. 718–728, 1996.

[197] C. J. Yeo, J. L. Cameron, T. A. Sohn et al., "Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes," *Annals of Surgery*, vol. 226, no. 3, pp. 248–260, 1997.

[198] T. A. Sohn, K. D. Lillemoe, J. L. Cameron, J. J. Huang, H. A. Pitt, and C. J. Yeo, "Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s," *Journal of the American College of Surgeons*, vol. 188, no. 6, pp. 658–669, 1999.

[199] B. Hristov, S. Reddy, S. H. Lin et al., "Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas," *International Journal of Radiation Oncology Biology Physics*, vol. 76, no. 1, pp. 176–180, 2010.

[200] A. L. Gleisner, L. Assumpcao, J. L. Cameron et al., "Is resection of peripancreatic or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?" *Cancer*, vol. 110, no. 11, pp. 2484–2492, 2007.

[201] B. Asiyanbola, A. Gleisner, J. M. Herman et al., "Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-fluorouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio," *Journal of Gastrointestinal Surgery*, vol. 13, no. 4, pp. 752–759, 2009.

[202] S. Tsai, M. A. Choti, L. Assumpcao et al., "Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study," *Journal of Gastrointestinal Surgery*, vol. 14, no. 7, pp. 1143–1150, 2010.

[203] C. J. Yeo, J. L. Cameron, K. D. Lillemoe et al., "Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality," *Annals of Surgery*, vol. 236, no. 3, pp. 355–368, 2002.

[204] C. J. Yeo, "The whipple operation: is a radical resection of benefit?" *Advances in Surgery*, vol. 37, pp. 1–27, 2003.

[205] T. S. Riall, J. L. Cameron, K. D. Lillemoe et al., "Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma-part 3: update on 5-year survival," *Journal of Gastrointestinal Surgery*, vol. 9, no. 9, pp. 1191–1206, 2005.

[206] D. M. Emick, T. S. Riall, J. L. Cameron et al., "Hospital readmission after pancreaticoduodenectomy," *Journal of Gastrointestinal Surgery*, vol. 10, no. 9, pp. 1243–1253, 2006.

[207] H. Nathan, C. L. Wolfgang, B. H. Edil et al., "Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective," *Journal of Surgical Oncology*, vol. 99, no. 2, pp. 87–92, 2009.